Ganaxolone in Posttraumatic Stress Disorder (PTSD)

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions
PTSD
Interventions
DRUG

Ganaxolone

200-600 mg bid, capsules, up to 12 weeks

DRUG

Placebo

capsules, bid, up to 12 weeks

Trial Locations (8)

20422

Washington DC VA Medical Center/ Uniformed Services University of the Health Services, Washington D.C.

27705

Durham VA Medical Center /Duke University Medical Center, Durham

29401

Charleston VA Medica Center/ Medical University of South Carolina, Charleston

45220

Cincinnati VA Medical Center/ University of Cincinnati, Cincinnati

92093

VA San Diego Healthcare System/ University of California, San Diego, San Diego

02130

VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital, Boston

03104

Manchester VA Medical Center/ Dartmouth College, Manchester

05009

White River Junction VA Medical Center/ Dartmouth College, White River Junction

Sponsors
All Listed Sponsors
collaborator

INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium

OTHER

collaborator

U.S. Army Medical Research and Development Command

FED

lead

Marinus Pharmaceuticals

INDUSTRY

NCT01339689 - Ganaxolone in Posttraumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter